G1 Therapeutics, Inc.
GTHX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $158 | $237 | $428 | $681 |
| - Cash | $32 | $95 | $221 | $207 |
| + Debt | $57 | $84 | $83 | $28 |
| Enterprise Value | $183 | $226 | $290 | $502 |
| Revenue | $83 | $51 | $31 | $45 |
| % Growth | 60.8% | 63% | -30.5% | – |
| Gross Profit | $75 | $48 | $29 | $45 |
| % Margin | 91.3% | 92.7% | 93.6% | 100% |
| EBITDA | -$34 | -$135 | -$142 | -$95 |
| % Margin | -41.6% | -263% | -452.6% | -210.9% |
| Net Income | -$48 | -$148 | -$148 | -$99 |
| % Margin | -58.1% | -287.6% | -471.3% | -219.2% |
| EPS Diluted | -0.93 | -3.38 | -3.54 | -2.62 |
| % Growth | 72.5% | 4.5% | -35.1% | – |
| Operating Cash Flow | -$38 | -$129 | -$132 | -$84 |
| Capital Expenditures | $0 | -$1 | $0 | $0 |
| Free Cash Flow | -$38 | -$129 | -$132 | -$84 |